AptamiR Therapeutics, Inc.

[Available On-Demand]
• Structure: AptamiR is an American modular Biotechnology Company developing pre-clinical drug candidates
• Mission: Treat fat accumulation, inflammation and fibrosis to cure related cardiometabolic disorders (obesity, dyslipidemia, diabetes and metabolic dysfunction-associated fatty liver disease (MAFLD)) without altering brain functions while improving quality of life of patients
• Strategy: Transform fat-storing cells (white adipocytes) into fat-burning cells (“browning effect”) to increase lipid oxidation, mitochondrial activity and energy expenditure
• Accomplishment to date: Proofs of efficacy for our first generation of oligonucleotides therapeutics (ONTs) targeting miRNAs achieved in human adipocytes in culture and in animal models
• Goal for the next 24 months: Complete the pre-IND and IND phases for the second generation of miR-22-3p Antagomirs to treat obesity, diabetes and fatty liver disease
• Gap to achieve this goal: Secure first tranche ($5M) of Series B financing
Company Type:
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
miR-22 antagomir
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
Founder & President
AptamiR Therapeutics, Inc.